JMP Securities Starts Incyte (INCY) at Market Outperform
More News related to INCY
- Results from Incyte's (INCY) Oral 11beta-HSD1 Inhibitor, INCB13739, Study Presented at ADA
- Results Presented at the ADA 69th Scientific Sessions Demonstrate that INCB13739, Incyte's Oral 11beta-HSD1 Inhibitor, Significantly Improves Glycemic Control, Insulin Sensitivity and Total Chole
- Unusual 11 Mid-Day Movers 5/29: JCG, STSI, PNSN, INCY Higher; CPRX, OCLS, GM, WTSLA Lower
- Incyte Provides Update on Special Protocol Assessment for INCB18424 as a New Treatment for Myelofibrosis
- Incyte to Present at Goldman Sachs 30th Annual Global Healthcare Conference
More News related to New Coverage
- Bank of America Resumes Coverage on Bristol-Myers (BMY) with a Neutral
- Credit Suisse Resumes Coverage on Rio Tinto (RTP) with an Outperform
JMP Securities initiates coverage on Incyte (Nasdaq: INCY) with a Market Outperform rating.
Incyte Corporation operates as a drug discovery and development company, which focuses on developing proprietary small molecule drugs to treat human immunodeficiency virus (HIV), diabetes, oncology, and inflammation diseases. [BCS]
Related Categories
New CoverageStocks Mentioned
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
